Chris Sheldon, AstraZeneca's former VP and head of investor relations
October 11, 2022 02:30 PM EDT
People
Pharma

As­traZeneca and GSK set­tle tal­ent feud in court — again

Nicole DeFeudis

Editor

As­traZeneca and GSK have set­tled their lat­est tal­ent skir­mish, clear­ing the way for 18-plus-year As­traZeneca vet­er­an Chris Shel­don to start a new gig at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times